Observational Study to Assess Adverse Events When Adult Female Participants Are Treated With Ubrelvy (Ubrogepant) During Pregnancy

Inclusion Criteria:

1. Within the United States.
2. Qualify as a prospective enrollment, defined as currently pregnant.
3. A diagnosis of migraine by the patient's health care provider (HCP).
4. Provide contact information for the participant and her and her infant(s)', if applicable, HCPs.
5. Authorize their HCP(s) to release maternal and infant medical information to the registry, upon request.

Provide sufficient information to confirm eligibility for 1 of following:

1. Ubrelvy-exposed women with migraine: adequate information to conclude that at least 1 dose of Ubrelvy was taken during pregnancy, including date(s) of administration.
2. Unexposed women with migraine (treated or untreated): adequate information to conclude that she has never taken Ubrelvy or discontinued Ubrelvy at least 3 months prior the first day of last menstrual period (LMP).

Exclusion Criteria:

1. Documentation of exposure to any gepants (acute or preventive) other than Ubrelvy from 5 half-lives prior to the first day of LMP or at any point during pregnancy before enrollment.
2. Women who are no longer pregnant (retrospective cases women for whom the pregnancy has already ended, and the outcome of pregnancy is known at the time of enrollment).